T. Rowe Price Investment Management
CORT icon

T. Rowe Price Investment Management’s Corcept Therapeutics CORT Stock Holding History

T. Rowe Price Investment Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,530
Closed -$541K – 704
2025
Q4 		$541K Sell
15,530
-8,909
-36% -$700K ﹤0.01% 652
2025
Q3 		$2.03M Sell
24,439
-541,830
-96% -$39.2M ﹤0.01% 613
2025
Q2 		$41.6M Buy
+566,269
New +$41.1M 0.03% 420

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

T. Rowe Price Investment Management's CORT Position: Q1 2026 in Review

T. Rowe Price Investment Management sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 15,530 shares — an estimated $541K sold.

T. Rowe Price Investment Management first reported a position in CORT in Q2 2025 and held it in 3 quarters. The position peaked at $41.6M in Q2 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • T. Rowe Price Investment Management reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 15,530 Corcept Therapeutics shares in Q1 2026, an estimated $541K.
  • T. Rowe Price Investment Management first reported a position in Corcept Therapeutics in Q2 2025 and held it in 3 quarters.
  • T. Rowe Price Investment Management's Corcept Therapeutics position peaked at $41.6M in Q2 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.